ZO Skin Health, Inc announced  that it has acquired the worldwide rights to ReFissa, as well as its generic equivalent tretinoin, from Suneva Medical. Refissa is the only FDA-approved prescription cream with a .05% strength emollient base designed to reduce fine facial wrinkles, correct irregular pigmentation, and smooth substantial skin roughness.

"This is a strategic acquisition for us," says Mark Williams, President, CEO and General Counsel for ZO Skin Health, Inc. "It allows the company to complete founder Dr. Zein Obagi's protocols, specifically those for hyperpigmentation. ReFissa is a best-in-class product that will deliver superior results and complement our existing portfolio of products."

A derivative of vitamin A, ReFissa'a new formulation of tretinoin has been proven in a clinical trial to be effective in the reduction of fine lines and tactile roughness of the skin, as well as in the treatment of irregular pigmentation from the sun. "Vitamin A has always been a critical component of my treatment protocol for my patients," says Zein Obagi, MD, Founder and Medical Director of ZO Skin Health, Inc. "It works in tandem with the ZO Melamix skin lightener to help blend the skin to create a more even skin tone. By acquiring ReFissa, we are able to offer to all of our physician partners a product with superior anti-aging and skin tone benefits so they can continue to prescribe in accordance with my protocols."

Financial terms for the acquisition were not disclosed.